Pavaka Wound Care Wins First Place by Peer Vote in Rev1's Concept to Customer Program, Accepted into Customer to Capital Accelerator
Updated: 7 days ago
COLUMBUS, Ohio — July 31, 2025 — Pavaka Wound Care has completed Rev1 Ventures' Concept to Customer program. Its final pitch was voted first place by the program's peer participants. On the strength of that performance, Rev1 has invited Pavaka into its Customer to Capital accelerator, which begins in August 2025.

Concept to Customer is Rev1's program for early-stage founders who are testing whether a real customer need exists and whether their solution fits it. Over the program, Pavaka's founders, CEO Brent Toto and CTO Frank Fischer, worked through structured customer discovery to sharpen the company's understanding of who will buy, use and pay for an electroceutical wound dressing.
Pavaka's investigational dressing, built on technology exclusively licensed from The Ohio State University, generates a low-level electric field at the wound surface. It is being developed for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms.
The peer vote carried particular weight because it came from fellow founders working through the same customer-discovery process, who chose Pavaka's story as the strongest pitch of the cohort.
The next step is Rev1's Customer to Capital accelerator. Over 14 weeks, it helps companies that have validated their market to win early customers, sharpen their competitive position, build financial and capital models, and prepare to engage investors.
Pavaka thanks the Rev1 Ventures team, the program mentors and its fellow Concept to Customer participants for their feedback and support.
What comes next: in the Customer to Capital accelerator, Pavaka will focus on moving from customer validation to the commercial, financial and regulatory planning needed to bring an investigational medical device toward market, working alongside Rev1's team and mentors.
Pavaka's founders bring complementary backgrounds to that work. CTO Frank Fischer spent 35 years at Cook Medical, and CEO Brent Toto brings wound care domain expertise.
"Winning the vote of our fellow founders meant a lot, because they understood exactly how hard the customer-discovery work is. It told us our story was landing well beyond the medical community." — Brent Toto, CEO and Co-Founder
Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.
About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.



Comments